MK-677 transiently raised leptin and leptin/fat ratio in obese men over 8 weeks
Background
Growth hormone (GH) deficiency and obesity are linked through dysregulated GH secretagogue receptor (GHSR) signaling, impaired lipolysis, and altered adipokine profiles. Exogenous GH therapy reduces total body fat but carries injection burden and side-effect concerns, motivating interest in oral GHSR agonists. Leptin, a key adipokine regulating energy balance, is elevated in obesity yet paradoxically underlies resistance to fat loss. Whether oral GH secretagogues like MK-677 modulate leptin, thyroid hormones, or gonadal hormones — all critical to fuel metabolism and body composition — had not been documented at the time of this study, leaving a significant mechanistic gap in their clinical characterization.
Study Design
A randomized, double-blind, parallel-group trial enrolled 24 healthy obese males aged 19–49 years with BMI > 30 kg/m² and waist:hip ratio > 0.95. Participants received MK-677 25 mg/day orally (n = 12) or matched placebo (n = 12) for 8 weeks. Serum samples were collected at baseline, 2 weeks, and 8 weeks to assess leptin, leptin/body-fat ratio, free T3, TSH, LH, FSH, total testosterone, and SHBG. Peak hormone concentrations were compared between arms using standard statistical tests with P < 0.05 as the significance threshold.
Results
MK-677 produced a statistically significant rise in serum leptin and the leptin/body fat ratio at 2 weeks vs. placebo (P < 0.05), but this elevation was no longer significant at 8 weeks, indicating a transient rather than sustained effect. Serum free T3 did not rise until 8 weeks of MK-677 treatment, at which point it was significantly elevated vs. placebo (P < 0.05), suggesting delayed thyroid axis engagement. Mean peak serum TSH was similar between groups at baseline and at 2 weeks, but by 8 weeks the MK-677 arm showed an increased peak TSH (P < 0.05 vs. placebo), though values remained within the normal reference range throughout.
MK-677 reduced serum total testosterone (P < 0.05 vs. placebo) at 8 weeks, yet the total testosterone/SHBG ratio — an index of free testosterone — was unchanged, implying a redistribution rather than a true androgenic deficit.
Peak serum LH and FSH concentrations were not significantly different between MK-677 and placebo at any time point, suggesting the gonadotropin axis was not the primary driver of the testosterone change.
Key Findings
- Serum leptin and leptin/body-fat ratio increased at 2 weeks (P < 0.05 vs. placebo) but normalized by 8 weeks
- Serum free T3 was significantly elevated at 8 weeks of MK-677 vs. placebo (P < 0.05)
- Peak serum TSH was increased at 8 weeks (P < 0.05 vs. placebo) but remained within the normal range
- Total testosterone was reduced by MK-677 (P < 0.05 vs. placebo) while total testosterone/SHBG ratio was unchanged
- LH and FSH peak concentrations were not significantly different between MK-677 and placebo at any time point
Why It Matters
Clinicians and advanced users should note the transient nature of leptin elevation — an effect that normalizes by 8 weeks — which suggests early adaptation in the leptin signaling axis and argues against long-term adipokine disruption from MK-677. The delayed free T3 rise at 8 weeks warrants thyroid monitoring in protocols extending beyond a month, particularly for individuals with borderline thyroid function. The fall in total testosterone without a change in free testosterone (via SHBG buffering) is a critical distinction for male users: blunt total-T readings alone could prompt unnecessary alarm or inappropriate intervention. Translating these findings clinically, MK-677's multi-hormone footprint suggests that 8-week cycles warrant a panel including leptin, thyroid, and sex hormone endpoints rather than GH/IGF-1 markers alone.
TitrateLab articles covering MK-677
Written by TitrateLab, separately from the study summarized above.
